Pulmatrix — Third Quarter 2026 Earnings Summary
Financial Performance:
- Total operating expenses for the three months ended September 30, 2026, were $1.2 million, compared to $0.9 million for the same period in 2025.
- Research and development expenses were less than $0.1 million for the three months ended September 30, 2026, compared to less than $0.1 million for the same period in 2025.
- General and administrative expenses increased to $1.2 million for the three months ended September 30, 2026, from $0.9 million in the prior year period, primarily due to merger-related activities.
- Net loss for the three months ended September 30, 2026, was $1.2 million ($0.34 per share), compared to a net loss of $0.9 million ($0.24 per share) in the prior year period.
- Net loss for the nine months ended September 30, 2026, was $3.4 million ($0.95 per share), compared to a net loss of $4.2 million ($1.16 per share) in the prior year period.
- Cash and cash equivalents totaled $1.4 million as of September 30, 2026, down from $4.1 million as of December 31, 2025.
- Restricted cash was $0.7 million as of September 30, 2026, with an additional $0.007 million in long-term restricted cash.
- Total assets were $2.4 million as of September 30, 2026, compared to $4.1 million as of December 31, 2025.
- Total liabilities were $1.0 million as of September 30, 2026, compared to $0.3 million as of December 31, 2025.
- Total stockholders' equity was $1.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025.
- Accumulated deficit increased to $(305.7) million as of September 30, 2026, from $(302.3) million as of December 31, 2025.
- 1,000 shares of Series B Convertible Preferred Stock were issued and outstanding as of September 30, 2026, with no shares issued as of December 31, 2025.
- Dividends accrued on Series B Convertible Preferred Stock were $0.02 million for the three months ended September 30, 2026, and $0.04 million for the nine months ended September 30, 2026.
Guidance and Future Outlook:
- The Company anticipates closing the proposed merger with Eos SENOLYTIX by the end of 2026.
- The Company anticipates its cash position is sufficient to fund operations at least through the anticipated closing of the merger.
- The merger closing is subject to Nasdaq's approval of the listing of shares to be issued, the completion of a reverse stock split approved on October 26, 2026, and other customary conditions.
- The Company is assuming it will continue as a going concern within one year of the financial statement issuance date.
Business Segments and Product Lines:
- Clinical development is currently on hold as the Company seeks to license or monetize its clinical assets.
- iSPERSE™ technology is licensed to MannKind Corporation and Cipla Technologies for certain fields of use.
- As of September 30, 2026, the iSPERSE™ patent portfolio included approximately 143 granted patents (17 U.S.-granted) and 47 pending applications.
- PUR1900 (inhaled itraconazole) received approval to proceed to a Phase 3 trial in India conducted by partner Cipla; Cipla expects to commence this trial in 2026.
- Pulmatrix will receive 2% royalties on net sales of PUR1900 by Cipla outside the United States.
- PUR3100 (inhaled dihydroergotamine for acute migraine) received FDA acceptance of an Investigational New Drug (IND) application and a "study may proceed" letter for a Phase 2 study.
- PUR1800 (Narrow Spectrum Kinase Inhibitor for AECOPD) showed no safety signals in a Phase 1b study and is supported for continued development.
- A private placement of Series B Convertible Preferred Stock was completed with an affiliate of Eos, raising $1.0 million in gross proceeds.
Market and Competitive Landscape:
- The Company is positioning its iSPERSE™ technology to exceed the performance of traditional dry powder particles for superior drug delivery compared to oral and injectable forms.
- The Company is seeking to monetize PUR1900 in the United States for indications where an orally inhaled antifungal may provide a therapeutic benefit.
Risks and Challenges:
- The Company's financial statements were prepared assuming it will continue as a going concern within one year.
- The merger closing is contingent on Nasdaq listing approval and the completion of a reverse stock split.
- Risks include the ability to divest clinical assets on favorable terms, maintaining Nasdaq listing standards, and the ability to raise future capital.
- Potential risks include delays in clinical trials, failure to establish product efficacy or safety, and the ability to obtain necessary governmental approvals.
Management Commentary and Tone:
- Peter Ludlum, Interim CEO, stated the focus has been on advancing steps to complete the merger with Eos SENOLYTIX.
- The Company obtained SEC effectiveness on its Form S-4 registration statement and stockholder approval for the proposed merger.
- Management expressed confidence in closing the merger by the end of the year.
Other Key Points:
- The merger agreement was originally announced on March 26, 2026, with Eos SENOLYTIX, a company developing gerotherapeutic peptides using the MitoXcel™ platform.
- If completed, Eos's business will continue as the business of the combined company.
- The Form S-4 registration statement was filed on July 9, 2026, and declared effective on September 25, 2026.
- A patent in India encompassing PUR1900 was awarded in July 2026 following a patent hearing.
- Phase 1 trial results for PUR3100 published in 2024 showed peak exposures in the therapeutic range and a lower incidence of nausea compared to IV administered DHE.
- The Company has 3,652,285 shares of common stock issued and outstanding as of September 30, 2026.
- Company
- PULMATRIX INC
- Sector
- Healthcare
- Industry
- Biotechnology